toxylact: a07bc03 crospovidone

The first professional lActological database in the word

Crospovidone (ATC A07BC03) is a non‑absorbed, cross‑linked polyvinylpyrrolidone polymer classified as an “other intestinal adsorbent”, used primarily as a pharmaceutic aid and enterosorbent, with negligible systemic absorption and a very low expected risk during breastfeeding.ebi+3

ATC A07BC03 overview

ATC code A07BC03 designates crospovidone within the subgroup A07BC “Other intestinal adsorbents”, part of the intestinal adsorbents class A07B among antidiarrheals. In addition to its classification as an antidiarrheal/adsorbent, crospovidone is widely used as a pharmaceutical excipient (tablet disintegrant and suspending agent) in many oral medicines.atcddd.fhi+5

Pharmacology and mechanism

Crospovidone is a synthetic, water‑insoluble, cross‑linked polyvinylpyrrolidone with high swelling capacity and rapid water uptake, which allows it to adsorb water and certain solutes in the gastrointestinal lumen. As an intestinal adsorbent, it can bind and immobilize various molecules in the gut contents, while its swelling and disintegrant properties help modify stool consistency and transit without systemic pharmacological activity.eureka.patsnap+3

Therapeutic and technological uses

Within A07BC03, crospovidone is categorized as an intestinal adsorbent for antidiarrheal use, though in practice its primary role is as a pharmaceutic aid (adsorbent, excipient) in oral formulations rather than as a stand‑alone antidiarrheal drug. As an excipient, it is incorporated into numerous tablets and capsules to ensure rapid disintegration and uniform dispersion, indirectly affecting the delivery of many active substances.ebi+4

Pharmacokinetics relevant to lactation

Crospovidone is a large, cross‑linked polymer that is not digested or absorbed from the gastrointestinal tract; it passes through the gut unchanged and is excreted in the feces. Because it does not enter the systemic circulation to a clinically relevant extent, it is not expected to be present in human milk in measurable amounts.drugs.ncats+2

Maternal safety profile

At the doses used in medicinal products and as an excipient, crospovidone is generally well tolerated and considered pharmacologically inert, with no specific systemic adverse effect profile when taken orally. Rare hypersensitivity reactions have been reported for polyvinylpyrrolidone derivatives in other contexts, but such events are exceptional and not characteristic of routine oral exposure.eureka.patsnap+2

Lactation safety assessment

General lactation principles and guideline documents emphasize that non‑absorbed oral agents and excipients are among the lowest‑risk categories, as they do not reach maternal plasma or breast milk in significant amounts. Given its non‑absorption, crospovidone is therefore considered to pose a negligible direct risk to breastfed infants, whether used as a classified intestinal adsorbent or as an excipient in maternal medications.who+5

Potential effects on the breastfed infant

Direct exposure of the infant to crospovidone via breast milk is expected to be essentially zero, so crospovidone‑related toxicity or interference with infant nutrition is not anticipated. Any potential risk for the infant in practice will derive from the active drugs formulated with crospovidone rather than from the polymer itself, so lactation risk assessment should focus on those active ingredients.who+5

Practical considerations in breastfeeding

When a breastfeeding woman receives an oral medication containing crospovidone—as an intestinal adsorbent or excipient—breastfeeding can generally continue without dose‑timing adjustments or special precautions related to crospovidone. As with other maternal medications, routine good practice is to use the lowest effective dose for the shortest duration and to monitor the infant for unexpected symptoms attributable to the active drug, not to the crospovidone component.who+2

Role among intestinal adsorbents

Compared with other A07BC adsorbents (pectin, kaolin, attapulgite, diosmectite), crospovidone has limited direct antidiarrheal evidence but a very well‑established record as an inert excipient and enterosorbent with negligible absorption. Its toxico‑lactological profile is therefore highly favorable, and it is unlikely to be a limiting factor in breastfeeding decisions when present in antidiarrheal products or other oral medicines.atcddd.fhi+5


Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.